Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.0
(3.45%)
SEK 3.0
(3.45%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 6.11 Million SEK | 308.76% |
| 2022 | 1.49 Million SEK | -64.0% |
| 2021 | 4.15 Million SEK | 50.87% |
| 2020 | 2.75 Million SEK | 51.9% |
| 2019 | 1.81 Million SEK | -45.54% |
| 2018 | 3.32 Million SEK | 2073.38% |
| 2017 | 153.17 Thousand SEK | 117.9% |
| 2016 | -855.51 Thousand SEK | -3.05% |
| 2015 | -830.2 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 2.36 Million SEK | -61.36% |
| 2024 Q3 | 7.25 Million SEK | 346.71% |
| 2024 Q2 | 1.62 Million SEK | -31.23% |
| 2023 Q1 | 1.41 Million SEK | -5.68% |
| 2023 Q4 | 6.11 Million SEK | 94.68% |
| 2023 FY | 6.11 Million SEK | 308.76% |
| 2023 Q3 | 3.14 Million SEK | 3.56% |
| 2023 Q2 | 3.03 Million SEK | 114.95% |
| 2022 Q1 | 3.83 Million SEK | -7.65% |
| 2022 Q4 | 1.49 Million SEK | -56.64% |
| 2022 Q3 | 3.45 Million SEK | -5.84% |
| 2022 FY | 1.49 Million SEK | -64.0% |
| 2022 Q2 | 3.66 Million SEK | -4.51% |
| 2021 Q1 | 2.64 Million SEK | -4.07% |
| 2021 Q3 | 2.63 Million SEK | 0.0% |
| 2021 Q4 | 4.15 Million SEK | 57.51% |
| 2021 FY | 4.15 Million SEK | 50.87% |
| 2021 Q2 | 2.63 Million SEK | -0.15% |
| 2020 Q3 | 2.1 Million SEK | 22.14% |
| 2020 FY | 2.75 Million SEK | 51.9% |
| 2020 Q1 | 1.74 Million SEK | -3.97% |
| 2020 Q2 | 1.72 Million SEK | -0.92% |
| 2020 Q4 | 2.75 Million SEK | 30.71% |
| 2019 FY | 1.81 Million SEK | -45.54% |
| 2019 Q2 | 3.33 Million SEK | -2.29% |
| 2019 Q3 | 3.63 Million SEK | 8.97% |
| 2019 Q4 | 1.81 Million SEK | -50.08% |
| 2019 Q1 | 3.41 Million SEK | 2.46% |
| 2018 Q1 | 3 Million SEK | 1862.5% |
| 2018 Q4 | 3.32 Million SEK | -10.37% |
| 2018 Q3 | 3.71 Million SEK | 13.7% |
| 2018 Q2 | 3.26 Million SEK | 8.67% |
| 2018 FY | 3.32 Million SEK | 2073.38% |
| 2017 Q2 | 1.00 SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 FY | 153.17 Thousand SEK | 117.9% |
| 2017 Q4 | 153.17 Thousand SEK | -94.77% |
| 2017 Q3 | 2.92 Million SEK | 292903100.0% |
| 2016 FY | -855.51 Thousand SEK | -3.05% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | -830.2 Thousand SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | -100.0% |
| 2015 Q2 | 1.00 SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2009 Q3 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2009 Q4 | - SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2008 Q4 | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | 10.586% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 94.955% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 94.955% |
| Arcoma AB | 28.02 Million SEK | 78.182% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 79.373% |
| BICO Group AB (publ) | 493.1 Million SEK | 98.76% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 90.2% |
| CellaVision AB (publ) | 126.03 Million SEK | 95.148% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -245.301% |
| C-Rad AB (publ) | 64.09 Million SEK | 90.46% |
| Duearity AB (publ) | 4.15 Million SEK | -47.031% |
| Dignitana AB (publ) | 7.41 Million SEK | 17.51% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -65.27% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.905% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 463.259% |
| Iconovo AB (publ) | -4.86 Million SEK | 225.771% |
| Integrum AB (publ) | 22.36 Million SEK | 72.654% |
| Luxbright AB (publ) | 8000.00 SEK | -76337.5% |
| Mentice AB (publ) | 14.1 Million SEK | 56.644% |
| OssDsign AB (publ) | 4.3 Million SEK | -42.077% |
| Paxman AB (publ) | 19.99 Million SEK | 69.423% |
| Promimic AB (publ) | 330 Thousand SEK | -1753.03% |
| Qlife Holding AB (publ) | 7.29 Million SEK | 16.141% |
| SciBase Holding AB (publ) | 11.91 Million SEK | 48.695% |
| ScandiDos AB (publ) | 22.69 Million SEK | 73.05% |
| Sectra AB (publ) | 36.59 Million SEK | 83.288% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 85.771% |
| Senzime AB (publ) | 20.34 Million SEK | 69.936% |
| SpectraCure AB (publ) | 1.00 SEK | -611499900.0% |
| Stille AB | 66.55 Million SEK | 90.812% |
| Vitrolife AB (publ) | 413 Million SEK | 98.519% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 95.682% |